News
Featured
For World TB Day 2024, the WGND is spotlighting a monumental achievement in TB drug research and development: the Global TB Drug Pipeline has never been bigger than it is today. The number of drug candidates being clinically evaluated for use in the treatment of adult pulmonary TB has surpassed that of all previous years. The WGND is tracking 19 drug candidates that have initiated or completed a Phase 1 clinical trial for use in treating Tuberculosis. Most have been or are currently being evaluated in a Phase 2 clinical trial and one has made it to Phase 3. These 19 do...
News
5 May 2010
Dr. Joel S. Freundlich Dr. Joel S. Freundlich attended Cornell University as a McMullen scholar and an Exxon scholar, attaining his B.S. degree with Distinction in Chemical Engineering in 1991 and his M. Eng. degree in Chemical Engineering in 1992. He received his Ph.D. degree in 1996 in Organic...
4 May 2010
Stop TB Partnership The Stop TB Partnership’s TB REACH initiative today announced the recipients of its first wave of grants to organizations that will engage in innovative approaches to increasing detection of tuberculosis (TB). Thirty applicants from 19 countries will together receive US$ 18.4...
3 May 2010
isoniazid structure Over the last month, a few reports about new positive TB cases have surfaced from FL, involving students at a couple of high schools and at a college. Information was not made available as to how the original infected TB individuals contracted TB. Furthermore, it is not clear...
2 May 2010
New research to speed TB drugs to those who need it most New York and Bangalore, India, May 3, 2010 The TB Alliance and AstraZeneca announced today at the 2010 BIO International Convention that they have entered into a research collaboration agreement to accelerate the discovery, development and...
29 Apr 2010
We first read this post at FierceBiotech.com . New drugs are needed to combat MDR-TB HAYWARD, Calif. and SHANGHAI, April 6 /PRNewswire/ — MicuRx Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development of antibiotics to treat drug-resistant bacteria, and Cumencor...
28 Apr 2010
Derived from the works of Paul-Henri Lambert, Tony Hawkridge, Willem A. Hanekom Clinics in Chest Medicine, 2009, vol 3. (4) pp. 811-26 TB patients awaiting treatment in Dhaka, Bangladesh photo: Jad Davenport Only one vaccine against tuberculosis (TB) now exists, bacille Calmette Guérin (BCG) ,...
26 Apr 2010
This post originally appeared at http://www.news25.us/Global/story.asp?S=12380174 Purdue Chao Center Purdue drug maker closing its doors after 5 years Associated Press – April 27, 2010 4:14 AM ET WEST LAFAYETTE, Ind. (AP) – An Indiana drug maker that’s North America’s sole manufacturer of a...
26 Apr 2010
How much does the nose know about TB? In a post a few weeks ago , we highlighted HeroRats , African-pouch rats, and their use for TB diagnoses. As described in that article, these rats are trained to distinguish positive TB samples verses negative TB samples presumably due to the release of...
25 Apr 2010
Stop TB Partnership The latest issue no.10 of Stop-TB News Monitor, for the period, 23-26 April 2010, is available online at: http://stoptb.citizen-news.org/2010/04/cns-stop-tb-news-monitor-23-26-april.html CNS Stop-TB News Monitor provides a snapshot of five major news pieces on tuberculosis (TB)...
25 Apr 2010
Open Forum 4: Key Issues in TB Drug Development August 18-19, 2010 | Addis Ababa, Ethiopia REGISTER NOW FOR: Open Forum 4: Key Issues in TB Drug Development August 18-19, 2010 | Addis Ababa, Ethiopia International Conference to address regulatory challenges to TB drug development in Africa. Don’t...
21 Apr 2010
Dr. Denis Mitchison in the lab When you think of true pioneers in research and development for the treatment of infectious diseases, Dr. Dennis Mitchison is sure to come to mind. For more than half a century, Dr. Mitchison has been dedicated to discovering new treatments for tuberculosis. Recently...
19 Apr 2010
UNAIDS is conducting a second-round assessment on the impact of the financial crisis on HIV treatment and prevention programmes. The first assessment was carried out in August 2009. Its findings were reflected in the report “Update on the impact of the economic crisis: HIV Prevention and Treatment...
19 Apr 2010
This article originally appeared in Clinical Infectious Diseases 2010;50:S260–S266 © 2010 by the Infectious Diseases Society of America. All rights reserved. 1058-4838/2010/5010S3-0026$15.00 DOI: 10.1086/651500 Mark Harrington is Executive Director of Treatment Action Group Tuberculosis (TB) and...
19 Apr 2010
World Health Organization The World Health Organization’s Stop TB Department has published the fourth edition of Treatment of Tuberculosis: Guidelines. The guidelines contain a number of new recommendations, including a call to discontinue regimens based on just two months of rifampicin (2HRZE/6HE...
19 Apr 2010
Despite the massive need for new TB drugs, the commercial viability of the TB drug market has long been viewed as questionable at best. Reports suggest that there is a substantial market that will grow year-over-year, though there is no firm conclusion about its commercial viability. The first...
